---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-003603"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:21:46.620368+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma files provisional patent for PSMA-targeted PARP inhibitor conjugates for prostate cancer therapy

## Summary
- Filed provisional patent for PSMA-targeted PARP inhibitor conjugates, co-invented by Dr. Alan Kozikowski who contributed to Pylarify and Pluvicto.
- Theranostic molecule aims to preferentially target prostate cancer cells, enhancing radiation and chemotherapy effects.
- Global PSMA PET Imaging Market was $1.5B in 2022, expected to reach $2.0B by 2030; Pluvicto market predicted at $2B.
- Shuttle Diagnostics subsidiary focuses on PSMA-B ligand and PC-Rad test for predicting RT outcomes in localized prostate cancer.

## SEC filing metadata
- accession: 0001641172-25-003603
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000164117225003603/0001641172-25-003603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000164117225003603/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-003603
- JSON: https://secwatch.observer/filing/0001641172-25-003603.json
- Plain text: https://secwatch.observer/filing/0001641172-25-003603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.